Emergent Technologies, Inc.
Thomas A. Harlan, Chairman, President, and Chief Executive Officer
800 Research Parkway, Suite 340
Oklahoma City, OK 73104
Phone: 405/271-3838
Fax: 405/271-3848
www.emergenttechnologies.com
ETI is a regionally-based venture capital and management services firm that specializes in forming, funding, commercializing, and managing companies for the purpose of converting institutional and university-based technology into high return ventures. Its unique process matches breakthrough technology with commercialization partners who can validate the market potential and expeditiously bring the technology to market. Investors can have confidence that risks will be reduced and the time to liquidity accelerated because ETI's process avoids unproven technologies, large front-end investments, and dependency on the IPO market.
ETI created its first investment fund, Emergent-OU, Ltd., in 1999 to launch three technologies emanating from the University of Oklahoma Health Sciences Center in Oklahoma City, OK. Its second fund, Emergent Technologies Oklahoma, L.P. was created in 2000 to make further investments in the first three companies and provided seed capital for the fourth and fifth companies.
Pure Protein has developed a unique method to produce soluble HLA protein from human cell lines. The company is focused on the discovery of new targets to prevent and treat infectious disease and cancer. Pure Protein's core technology platform allows the production of large quantities of immune surveillance proteins and provides unique insight to the inner workings of diseased cells. It has created two subsidiaries, Pure Transplant Solutions, L.L.C. and Pure Vaccine Solutions, L.L.C. The Pure Protein platform enables a distinct toolset for evaluating and improving vaccines as well as reducing unwanted allergic reactions from bio therapeutics. www.pureproteinllc.com
Hyalose, L.L.C. has developed unique capabilities for the recombinant production of hyaluronic acid both in bulk production using fermentation and in enzymatic synthesis where a very high level of control is possible in determining the exact molecule that is synthesized. Controlled enzymatic synthesis also enables the placement of other glycosaminoglycan sugars and unnatural sugars at precisely defined positions in the sugar chain creating new novel sugar compounds. The company has licensed several genes from different species of bacteria that synthesize hyaluronic acid. www.hyalose.com
MedUnison
– Formerly known as MedSynergy, MedUnison's DocSynergy is an online,
secure medical community for physicians and other healthcare providers
to dramatically improve the quality of healthcare delivery, while
significantly lowering the cost of treatment. The DocSynergy solution
harnesses the benefits of distance medicine through unique technology to
enable physicians to tap the expertise and knowledge of colleagues
regardless of location. The DocSynergy solution is built for the rural
physician, the urban specialty group, and physicians working with
captured patients, such as those in correctional facilities. www.medunison.com
Heparinex,
L.L.C. is a biopharmaceutical company focusing on the novel recombinant
synthesis of compounds for the growing anticoagulation market and
associated arenas. The core technology platform was originally
discovered and patented by a leading carbohydrate chemist/
glycobiologist at the University of Oklahoma in 2002. Heparinex’s core
platforms employ (a) bacterial production techniques and (b) in vitro
defined polymer syntheses to provide uniquely controlled non-animal
sources of genetically customizable heparinoid compounds for drug
discovery, therapeutic formulations and medical device applications. www.heparinex.com
Choncept
is a biotech company focused on development of new technology to
produce chondroitin from fermentation of recombinant bacteria to replace
the current chondroitin source of beef and other animal by-products.
Chondroitin produced by the gene patented by Choncept is unsulfated
which can be sulfated to produce chondroitin similar to that isolated
from animal sources. The unsulfated chondroitin may also be of interest
as a biomaterial. Chondroitin produced recombinantly may be
significantly less expensive to produce than current methods that rely
on animal by-products. Modified chondroitin, dermatan sulfate, has
properties as an anti-coagulant, an important pharmaceutical market. www.choncept.com